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ABSTRACT 
l though Ep tein-Ban \iru ( EBV)  i s  often found in human tonsi ls  and adenoids, i t  
r main to b preci ely determined in what cel l s  and microen ironment the virus is  
pre ent .  ! though general ly regard d as a B lymphotropic virus, E BV can infect non­
B-ce l l  . The aim of this project is  to detelmine the prevalence of EBV in the tons i ls  
and adenoid of the nited Arab Emirates (UAE) Nationals and to provide a basis for 
understanding th  origin and biology of EBV - infected B and non-B cel ls ,  the 
immunophenotyp of a l l  EBV - infected cel l s  in reacti e tonsi ls  was determined by 
ubject ing ton i l  and adenoid section of 46 cases ( 92 specimens) to EBER in situ 
hyblid ization and immunohistochemistry with monoc lonal antibodies to T-ce l l s  
( C D  ) ,  B-ce l l s  ( C D20) and epithel ial cel l s  ( cytokerat in) ,  a wel l  as  immunostaining 
\\' i th anti bodies to EBV latent proteins LMP- l .  EBV is  found in 43% of tonsi l l ectomy 
pecimens and 15% of adenoidectomy spec imens. Nearly a l l  E BV - infected cel l s  are 
found to be B lymphocytes. About 90% of the EBV - infected cel l s  are found in the 
interfol l icu lar regions of tonsi l s  and adenoids and the remaining 1 0% are found within 
the fol l i c les. There i s  no significant association between E BV i nfection and age ( P= 
0 .324)  and gender ( P= 0 .442 ). I n  conc lusion EBV is associated with tonsi l l er 
hypertrophy and is prevalent in  43% of our cases. I n  situ hybridization i s  the gold 
standard method for the detection of EBV in  t issue. 
v 
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membranous tammg for C D20 u ing alkal ine phosphatase 
detection kit ,  X400 
Tons i l lar t issu with double staining technique showing double 
tained cel l s  for EBER (arrow),  In  s i tu h brid ization, and red 
membranous taining for C D20 using alkal ine phosphatase 
detection kit, 1 000. 
Ton i l lar t i  sue with double staining technique showing double 
stain d cel l for EBER ( arrow), In situ hybridization, and brown 
membranous staining for C D20 using ABC-DAB detection kit ,  
400. 
Ton i l l ar t issue with double staining technique showing double 
stained cel l for EBER (arrow), In situ hybridization, and brown 
membranous staining for C D20 using ABC-DAB detect ion kit ,  








1. 1. The To nsi ls  a nd Adenoids 
Ton il and adenoid ar col lecti n of lymphoid t issue found in the throat. 
Both ton i l  and adenoid function to ti lter bacteria and viruses entering through the 
no e or throat . Ton i l  and adenoids fOIm part of the" Waldeyer's ring which 
compri e the nasopharyngeal tonsiL or adenoid, attached to the roof of the pharynx, 
the paired tubal tons i l s  ituated at the phyaryngeal openings of the Eustach ian tubes, 
the paired palatine tonsi l  are posit ioned in the oropharynx and the l ingual tonsi l  on 
th posterior third of the tongue".(l )C see figure 1 )  
AdenOId 
----
Figu re I: Wa ldeyer' R i n g  (I) 




The tons i l s  are lymphoepithel ial structures that provide a protective 
immunological ring at the openings of both d igestive and respi ratory tracts. (I) 
Palatine tons i l s  C PT)  consist of an extensive ystem of crypts or gypsy-wel ls, 
generating a l arge internal surface.  The tonsi ls  contain four lymphoid compartments 
part ic ipating in the immune functions, namely the reticular crypt epithel ium ,  the 
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e 'traf'o l l icular area. the mantle zone r lymphoid fo l l ic le , and the fol l icular germinal 
center . In human palatine ton il the v ry fir t part exposed to the outside 
em irolUnent i ton i l lar epithel ium.  (2. J) ( figure,2, 1 3 )  
Th human PTs are covered by tratified quamous nonkerat inized or 
parakeratinized pithe l ium that extends into deep and part ly branched crypts, of which 
th re are about 1 0  to 30 .  The crypt great ly increa e the contact urface between 
m irolUnental in fluence and lymphoid ti ssue. By contrast ; the epithel ia  l i ning the 
crypt are not uni fonn .  They contain patche of ret iculated, morphological ly  re haped 
and rearranged stands of epithel ia l  cel i s, which are infil trated with nonepithel ial cel l  
(mainly lymphocyte ) .  and are underlined with disrupted basement membrane but no 
thick connective t is  ue band. A vast continuum of intercel l ular spaces are formed 
between the epithel ia l  cel l s  with their slender cytoplasmic processes, which are fi l led 
with mobi le and mot i le free ce l l  such as T-cel l ,  I gG , IgA ,and IgM produci ng B- cel ls, 
macrophages, interdigitat ing dendritic cell ( I Des)  and langerhans cel l s  ( LCs) .  
I nterestingly, there i s  a net ork of intraepithel ial blood vessels within the tonsi l lar 
lymphoepithe l ium. I n  both, the tonsi l s  and adenoids, the capi l laries are arranged in 
loops oriented perpendicularl to the crypts surface, and h igh endothel ial venules are 
located in  the lower border regions of many ret iculated patches. (1.3) 
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1. 1 .2. Pharyngea l ton it 
denoid . un l ike the ton i i , have pseudostrat iIied col umnar c i l iated 
epithel ium. [hey al 0 differ from the th r ton i l  types by lacking crypts. Pharyngeal 
and palatine ton i l  . al though located in di fferent region of the upper aero-digestive 
tract. are thought to protect the respiratory tract imi larly against infections by 
induc ing and di eminating T and B cel l s. (5) ( ee figure 1 4) 
I.2. E pste in  Ba rr Vi rus ( E BV )  







Fig u re 3: St ruct u re of E BV v i r u s  (6) 
< gp350 
< gH 
Commonly causing infectious mononucleosis EBV i s  named after Michael 
Epstein and Yvonne Barr. who together with Bert Achong, discovered the v irus in 
1 964 . EBV or human herpesvirus ( H HV -4) is  a member of y I-herpesvirus. I t  is  an 
enveloped virus that has double-stranded DNA surrounded by an icosahedral 
nuncleocapsid containing 162 capsomeres there are three major capsid proteins. The 
nucleocapsid is in tum enclosed by a protein tegument, which is enclosed by a viral 
envelope that consists of mult iple v iral glycoproteins.  EBV has a genome comprised 
approximately 172 nucleotide base pairs. (7) E BV has a l i near genome which is 
characterized by di stinctive sequence rei teration. At the termini  (TR)  there are 20 
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cople or a 500 ba e pai r repeated equence that i complementary and therefore 
permit c ircu larization of the l inear genome to form the BY pisome and there is a 
fi:-..ed number of TR in a gi en cel l .  Anal i s  of the TR in E BY associated 
mal ignanc ie ha b en u ed to ascertain whether the tumor arose from a single EBY 
inf ted cel l  and there i internal direct r peats ( I R ) .  (8) ( ee figure 4 )  
a EBV electron micrograph b EBV genome: latent genes 
EBERl EBER2 
-, 
- Dc .ule·s'rar'cfP'(j DNA e(JISOflle 
C Open reading frames for the EBV latent proteins 
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Figu re 4: ( a )  E BV elec t ron mic rogra p h  ( b) E BV genome (c)  Open reading fra mes 
(16) 
The E B Y  episome i s  the molecular basis for l atent infection, it is a c ircular 
intrace l lu lar form of genome i t  maintains a persi stent relationship within the celL l ike 
an autonomous piece of DNA situated in the chromatin .  the episome i s  repl icated by 
host D A polymerase each copy of the EBY episome i s  repl icated only once during 
the cel l cycle. 0 that constant numbers are maintained from one cel l generation to the 
next which is part of the mechanism of persi stence of the EBY genome in latency. 
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OYer 70 open reading frames al lo\\- for the transcript ion of genes for a large number 
of di fTerent \ iral proteins. Expr ion of different combinations of the e proteins 
al lo\"\ for the viru to e tabl i sh different fOIm of infect ion (9. 10). I t  i s  one of the most 
common human i ruse that infect more than 90% of the world's popUlation. (10. 11.12) 
EB the fir t \ i ru a ociated \\-'i th human malignancy. Infection with Epstein-Barr 
\ lru a ociated with Iymphoprol iferative disorders, especial ly  111 
immunocompromi ed ho t , and it is a lso associated with various types of tumors, 
inc luding nasopharyngeal carc inoma and Burk itt 's lymphoma, commonly cause 
infectious mononuc leo is, Hodgkin 1 mphoma ( H D),  gastric carc inoma (I3) which 
often does not have any ymptoms but EBV shares a tropism for B lymphocytes and 
ha a propen i t)' to oncogenic ity. (l.J) 
PrimaI) i nfection occurs by the oral route and, at least as witnessed in  1M 
pat ients. i s  characterized by exten ive repl icat ion of the v irus in  permissive cel ls, 
probably mucosal epithel ia l  cel l s  c losely associated with pharyngeal lymphoid t issues 
(I·U5 )  thi leads to the release of high t iters of infectious virus  into the throat . At the 
ame time, the v irus  in i t iates latent growth-tran forming infections within the B-cel l  
pooL best visual ized in  tons i l s  from I nfectious mononuc leosis (1M) pat ients. (15) 
The genome of E B V  consist ing of TR, I R  and U regions. The genome encodes 
about 90 rep l icat ion proteins .  
1.2.2.  Viru repl ication 
EBV infects epithe l ial cel l s  i n  the oropharynx and rest ing B-ce l l s . I nfection of 
epithel ia l  ce l ls  resul ts in al lytic effect with rep l ication of the v irus and release of 
virions from the cel l .  During lytic repl ication, the v iral  genome is copied by the i ral 
o A polymerase. (8. 17) 
I n  contract. infection of primary B-ce l l s  usua l ly  results in a l atent infect ion 
with expression of only eight proteins without production of virions. These latent ly 
infected B-ce l l s, termed Iymphoblastoid cel ls ,  are transformed or immorta l ized and 
can repl icate indefinitely. (8) 
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L2.3. Latent i n fect ion  
nl)  a few of th nearly 1 00 EBV gene are e pressed during latent infection. 
Th e latent gen s are the ix EB , tv 0 latent membrane proteins ( L M Ps), two 
E B  encoded RN ( EB E Rs) ,  and transcripts from the Bam R IA region of the 
genome. Only two of the e gene , EB  A- I and LMP- l ,  are expressed during lytic 
inf ction. Genetic tudie have shov.;n that five of these genes are essential for B cel l 
tran fom1at ion by EBV in itro. ( 1. 8 ) 
I. 2.4. E pste i n-Ba rr vi rus latency p rote ins  
1 .  E p  tein-Barr v i ru N u clear Antigen ( E BNA- 1)  
EB A- I i expres ed during latent and lytic infection and the protein 1S 
pre ent in  a l l  EBV -a ociated tumor , E B  A- I i s  essential for transformation of B­
cel l by EBV. (18) E B  A- I binds to a sequence o n  the E B V  genome termed ori P and 
as ociated with m itotic chromosomes. The ori P sequence is the origin for v iral  DNA 
rep l ication and consi ts of number of repeated elements that fonn the binding site for 
E B  -1. Binding of E B  A- I to ori P and its association with chromosomes al lows 
the viral  genome to be maintained during division of the cel l .  (8 ) EBNA- l also 
transactivates gene expression, .  upregulates its own expression, has the abi l i ty to 
i nh ibi t  its own degradation i thought to al low cel l s  expressing the protein to avoid 
destruction by c lass I restricted cytotoxic T-cel l .  Transfer of the glycine- alanine 
repeats to other proteins al lows the latter to a oid degradation in proteosomes. (19) 
2 .  E p  tein-Barr v i ru N uclea r Antigen ( E BNA- 2 )  
E B  A-2 i s  required for B-ce l l  transformation by the virus. 
(20, 21) E BNA-2 
upregulates expression of both v iral and cel lu lar proteins.E B  A-2 upregulates 
E B  A- I through the Wp and Cp promoters. EBNA-2 also st imulates expression of 
LMP- l and LMP-2. (22'E B  A-2 upregulates expression of C D2 1 ,  C D23 .  c-fgr, and c­
myc . (23, 24. 25) CD2 1 i s  the EBV receptor and C D23 i s  expressed on the surface of 
EBV transformed B- cel l .  (8 ) 
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3. Ep tein-Barr v i ru uclea r An tigen ( E BNA-LP)  
- LP i the 5 '  gene encoded in a transcript with the EBNA-2 gene. 
Whi le EB - LP ha not b en proven to b e ential for tranSfOl1l1ation; deletion for 
the carboxy tel1l1 inu of the prot in marked I reduce the abi l i ty of the v im to 
tran form B- c I I .  (26) 
EB - L P  augment the abi l i ty of  E B  -2 to act ivate expression of LMP- l ,  
L IP-2 (27\ and cel lular protein (28) hi le E BNA-LP has been shown to bind to p53 
and th ret inobla toma protein . (29) I t  i unc lear what signiticance these interactions 
ha\'e for the role of E B  A- LP  in B-ce l l  tranSfOl1l1at ion. I n  addition EB A- Lc  binds 
to a number of other cel lu lar proteins i nc lud ing heat shock protein 70, D A protein 
k ina e cata lyt ic subunit. HA95 (A nuclear protein  that may be involved in mitosis 
),and a and p tubul in .  (30) 
4. E p  tein-Barr v i ru N uclear An tigen ( E B NA- 3) 
There are three EB A-3 proteins. E BNA-3 B,  and E BNA-3C which show 
weak homology to each other and are present in tandem in the viral genome. E BNA-
3A and E B  A-3C are required for B cel l  transfoffi1at ion by the virus, whi le EB A-3 
B i s  d i  pen able (31 . 32) .The EB A-3 proteins a lso upregulate expression of cel lu lar 
and viral genes. E B  A-3C increases the expression of C D2 1  and L M P- l (33.34). and 
E B  A-3 B upregulate expression of C D40 and bc1-2. (35) E BNA- 3C interacts with 
the human metastatic suppre sor protein Nm 23 -H I  and i nh ibits the abil ity of the latter 
to suppress the migration of Burkitt lymphoma cel ls .  (36 
S. E p  tei n-Barr v i rus Membra n e  P rote in  ( LMP-l) 
L M P- I is expressed in both latently and lyt ica l ly infected B-ce l l .  LMP- I IS 
requi red for transformation of B cel l s  by EBV.  (37) L M P- l functions as an Expression 
of L M P- l in cel l s  upregulates a l arge number of proteins and results in mult iple 
phenotypic changes. L M P- l stimulate expression of intracel lu lar adhesion molecules 
(rCAM ) - 1 .  LM P-l can also inhibi t  the abi l i ty of E BNA- l to transactivate the EB A 
C P  and L M P- l  promoters and inh i bits BZLF I transcription and induction of lyt ic  
repl ication. (38) L M P- l i s  critical for B-ce l l  pro l i ferat ion and development of 
lymphomas in vivo. LMP- l has several antiapoptotic effects on the cel l .  LMP- I 
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upregulated expre ion of 20 are upregulated in tran genic mice e pressing LMP-
1 .  ( 39) LM P-l al 0 inhibit e. pres ion of c-m c and thereby further protects cel l  from 
ap pto i . (40) 
6. Ep tein-Barr v i ru Membra ne Protein ( LMP-2 ) 
T\\ o f0D11 of LM P-2 are e. pre sed in E BV - infected B- cel ls .  LMP - 2A and 
LMP-2B are col l i near. except that they d iffer in their 5' exons. The resultant proteins 
are indent ical except that LMP- 2A i s  predicted to have an addit ional 1 1 9 amino acids 
at it  amino tenninus compared with L M P- 2 B. LMP- l and LM P-2 colocal ize in the 
member of B-ce l l .  (4 1 ) LMP-2 i not required for B- cel l  transfonnation. (42) LMP- 2 
functions to pre ent EBV react ivation in  latently infected B-cel l s  .Cross-l ink ing of 
immunoglobul in on the surface of E BV transfonned B lymphoma cel l s  in the absence 
of LM P-2. (8) 
7. E pstein-Barr v i rus ( E B E Rs) 
Two polyadenylated, nontranslated RNAs, E BER- l and EBER-2, are 
expressed i n  latent ly infected EBV - transfonned B-cel l .  They are the most highly 
expressed EBV RNA in latently infected cel i s, and probes to these transcripts have 
been u ed extensively for the detection of EBV in t i ssue. (5. 8) 
8. Other latency-associated gen es 
A num ber of EBV transcripts encoded in  the right ward direction from the 
Bam HI- A region of the genome have been detected in EBV - infected B-ce l l  and 
nasopharyngeal carcinomas. (
43 ) These BamHI- A rightward transcripts include the 
BARFO and RPMSI  genes. Transcripts conesponding to the BARFO gene have been 
detected in l atently infected B-cel l s.(
44) At present BARFO protein  have not been 
detected in latently infected cel l s, although antibodies to the protein have been found 
in patients with nasopharyngeal carc inoma.(45 ) 
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1.2.5. Lytic infection 
Dur ing \)1 i infection, a large number of viral genes are expres ed. In  addition 
to protein r quired for yiral D repl ication and for assembly of virion, the virus 
eyeral prot ins that modulate the immune respon e. These proteins block 
upopto i and inhibi t  the act ivity of interferon alpha and interferon gamma. 
(8. 17) 
E B V  encode approximately  90 proteins that are expressed during lyt ic  virus  
repl ication: the e protein are c lassi fied as  immediate early, early and late proteins. 
Immediate early genes are transcribed after infection in  the presence of protein 
synthe i inhibitor , whi le late genes are not transcribed when these i nh ibitors are 
pre ent. I n  general ,  immediate early genes are important for regulating gene 
expre sion in the v irus , earl proteins encodes enzyme that are important for v iral 
o A repl ication, and late proteins encodes structural proteins of the v iron.  E BV lytic 
genes are named by the Bam H I - A fragment in which they are located .whether they 
are expressed in a leftward ( L )  or rightward direction ( R) ,  and the number of their 
position in  the Bam H I - A fragment. (8) 
1.3. E pide m iology of E pste i n-Ba rr virus 





Source Okano. M (1989) 
Fig u re 5: Epstein -Ba rr viru -a ociated Bu rkitt ly m phoma & nasopha ryngea l carcinoma (-16) 
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B found worldwide, and infection i rtua l l  Lmiversa l .  I n  
underdev loped countrie , mo t infant are infected a ymptomatical ly within the fir t 
) ear of l i fe. 0 t people ar infected within the first three decades of l i fe;  the 
infection i often a ) mptomatic or undiagno ed. Typical l , Infect ious mononuc leosi s 
( I  1 )  occur in adole cence and the early third decade of l i fe and rarely in older 
peopl . The \. iru pr ad from person to person by c lose contact and exchange of oral 
ecret ion occurs during ki sing, thus the nickname the k iss ing d isease. Al though 
there are no epidemic of 1M, the incidence is h igher in col lege students in early fal l  
and winter, \" hen seme ter begin,  presumably because of new opportunit ies for virus  
expo ure. The incubation period, variable and d ifficult  to  est imate because of the 
in id ious on et, i about 4 to 6 weeks. The geographical d istributions of EBV 
a oc iated neoplasms indicate a possible as ociation with potential cofactors. The 
i mm unosuppressive potential of malaria has been suggested as a cofactor in the 
progre ion of chronic or latent E BV infection to endemic African Burki tt's 
l ) mphoma ( FBL) .  ( See figure 5 )  The restrict ion of nasopharyngeal carcinoma to 
people l i \' ing in certa in regions of China has indicated a possible genetic 
predi po it ion to the cancer or possibly the presence of cofactors in  the food or 
environment . (S.49) 
Transplant recipients, patients with acquired immunodefic iency syndrome 
(A ID ). and geneti cal l immunodeficienct people are at high risk for 
lymphophro l i ferative d isorders ini t iated by E BV. These may appear as polyc lonal and 
monoclonal B cel l lymphomas. These people are also at high risk for the development 
of hairy oral leukoplakia. (47.4S) 
1.4. Pathogenesis of E pstein-Ba rr virus 
The virus infects the  oropharynx, where i t  repl icates in epithel ial cel ls. The 
v i rus is then shed in to the sal i va and accesses B cel l s  in the lymphat ic t issue and 
b lood . Infection leads to the production of E BV proteins, inc luding the early antigens 
v iral capsid antigen, and the glycoproteins of the membrane antigens. 
EBV is a B-cel l mitogen that st imulates growth, prevents apoptosis 
(programmed cel l  death ), and immortal izes the cel l .  EBV infection of the B cel l  also 
11  
alter the \.\a) in \.\hich it interact with the re t of the immune tern. EBV enhances 
the expre i n of c II urface proteins uch a hi stocompatibi l i ty leukocyte antigen. 
adhe ion protein , and the CD23 blast antigen and encodes an analogue of 
interlcukin- 1 0  (B RF- l ) . B RF- l promote immune escape by inh ibit ing TH I 
helper T-cel l , inc luding interferon- gamma ecretion and early T-cel l  re ponses to the 
\ l ru \\ h i le promoting B-cel l  growth and I gO ynthesis. Continued B-ce l l  
pro l i ferat ion in conjunction with the effects of other cofactors may result in the 
de\ elopm nt of l y mphoma. (.j9) 
I nfectiou mononuc leosi re lilts from a c i  i I war between the E BV infected 
B-ce l l  and the protect ive T-cel l .  The c lassic Lymphocytosis associated with infection 
mononucleo is result mainly from the activation and pro l i ferat ion of T-cel ls .  These 
appear a atypical lymphocytes (a lso cal led Downcy cel l ) . They increase in number in  
the peripheral blood during the second week of infection, accounting for 1 0% to 80% 
of the total white cel l count at this t ime. The large T-cel l response causes the swol len 
lymph gland , spleen. and l iver, which occur later in the disease. (22) 
T-cel l  l im i t  the prol i ferat ion of EBV infected B-cel l in t issue culture and are 
es entia l  i n  contro l l i ng the disease. I t  i s  difficult  for EBV i nfections to resolve in 
people with impaired cel l mediated immun ity, and B-ce l l  lymphoprol i ferat ive 
di ea es may result .  
(22)
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1.5. E pste in  B a r r  vi rus a nd la boratory diagnosis 
EBV induced I M  is usual ly documented by the finding of atypical 
lymphocytes, lymphocytosis ( mononuc lear ce l ls  constituting 60% to 70% of the white 
blood cel l COWlt with 30% atypical lymphoctes), heteroph i le ant ibody, and antibody 
to v iral ant igens. Virus i solation is not practical . D A probe analysi s and 
immunofluorescent identification of viral  ant igens are used to detect evidence of 
infection. 
Atypical lymphocytes are probably the earl iest detectable indication of an 
EBV infection. These cel l s  appear with the onset of symptoms and disappear with 
resolution of the d i sease. 
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I Ieterophi le  anti body result from the non pec i fic,  mitogen l ike act ivation of 
B- ce l l  by  EB and the production of a ide repertoire of ant ibodie . These 
antibodie inc lude IgM heterophi le  ant ibody that recognizes the Paul - Bunnel 
antigen on heep, horse. and bovine erythrocyt s but not that on guinea pig kidney 
cel ls .  The heterophi le ant ibody re ponse can u ual ly be detected by the end of the first 
\v ek of the i l lne and la ts for a long as e eral month . It i an excel lent indication 
of EBV infection in adult . The mono pot and ELI SA are rapid and widely used for 
the detection of the heterophi le antibod . (8) 
Serological tests for antibod to v iral  ant igens are useful in patients whose 
E BV infections cannot be diagno ed on the basis of the u ual c l in ical criteria and the 
re ults of heterophi l e  antibody te t. Recent EBV infection is indicated by the finding 
of any of the fol lowing: 1 .  IgM antibody to the viral cap id antigen ( YCA),  2 .  The 
pre ence of VCA antibody and the absence of EBNA antibody. 3 .  Arising E BNA 
ti ter. or 4 .  An e levated VCA and early antigen ant ibodies. The finding of  both VCA 
and EB A antibodies in serum indicates that the person has had a past infection. (8. 22) 
The direct detection of latent E BV infection i s  a lso a method of d iagnose 
u mg E BV Latency associated antigens by immunostain ing for LMP or EBV­
Encoded RNA (EBER)  by I S H .  On our study we used these two methods to detect the 
E BV. 
1.6. E pste in  Barr  Vi rus pers istence i n  vivo 
The behavior of E BV in normal condi tions, is to ini t iates, establ ishes, and 
maintains persistent infection within the memory B- cel l s .  
econd, membrane fusion occurs, a l lowing entry of the E BV nucleocapsid and 
tegument in to the host cel l  cytoplasm and these post attachment events involve the 
interaction of a v iral glycoprotein complex ( including the v iral gH and gL homologs, 
1 .6. 1. I n i tiat ion 
At this step first the E BV wi l l  attach it e lf to B-cel ls, via the interaction of the 
EBV gp3 501220 envelope glycoprotein with the C D2 1  molecule on the B-cel ls .  
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\-vel l  as the gp 42 m lecule)  with hi tocompatibi l i t comple ( M H  ) .  (49) 
fter the entry. the \ , lru part ic le i di -a embled and the genome i s  
tran ported to  the nucleu , where a tate of i ral latenc is rapidly establ ished . This is  
a ciated v. ith the activation. pro l i feration and immortal ization of the latently 
infected B- ell . ( 1J )  
The abi l i t) of EB to induce B-ce l l  growth transformation to pennanent 
Iymphobla toid cel l  l ines is a mult istep process. first EBV induces mature resting B­
ce l l  to become activate, and to enter the cel l  cycle  going from a Go, or resting state, to 
G 1 , thi in i t ia l  step occur as a result  of EBV mediated cross l i nk ing of the C D2 1  
molecule, and is associated " ith secretion of immunoglobul in and with cel l  c lumping, 
\" hich increa e local cel l den i ty and occurs as the result of the upregu lat ion of 
ce l lu lar adhesion molecule . Second. the EBV infected cel l  begins to pro l i ferate 
depending on h igh cel l density and on the autocrine production of B-ce l l  growth 
promoting cytoki nes. Buy the t ime, EBV i nfected cel l  continue to pro l i ferate and 
eyolve i n  to more rapidly growing ce l ls  that are less dependent on autocrine growth 
mechanisms. (48) 
1 .6. 1 .  Establ ish ment  
To understand the persi stence of EBV in vivo, it 's necessary to  understand the 
nature of B lymphocyts in Iymphoepithel ium of tonsi ls  and adenoids. 
In the normal tonsi ls ,  environmental ant igens entered to the mouth are 
continuously sampled by the epithe l ium of the tonsi l  and adenoids, underneath the 
I mphocytes i f  the antigen is recognized by the antibody on the surface of the naive 
B-cel l s, it wi l l  bind and cause the B-cel l  to become activated blasts and m igrate into 
the fol l ic le to form a germinal  center, then the cel l s  undergo round of rapid 
pro l i feration associated with i sotype switching and mutation of the immunoglobul in 
genes, fol lowed by competi t ive selection for those with the antibody that binds the 
antigen best. Those who lose in the competition to bind ant igen die by apoptosis .  
Ul t imately the surv iving cel l s  leave the center as memory cel l s  primed to make a 
rapid response to rechal lenge with the antigen. This process requires, in addit ion to 
the anti gen, a signal to the B cel l from an antigen-speci fic T helper cel l .  (I) 
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Being a gammaherpe v i ru . EBY ha both latent and lytic state in it l i fe 
cyc le: the latent infection i pred minant, whi l the lytic c c 1e  can be condit ional ly 
reacti, at d. In latenc) , B can e. pres a fe\\ so-cal led latent protein , including six 
E B  nuclear ant igen ( E B  ) and three latent membrane proteins ( L M Ps). When 
the B 1) tic cycle  i induced. an e pression cascade of numerous lyt ic genes occurs. 
re ult ing in the repl ication of v iral genomes and the production of virus part ic les. ( 1 7 ) 
EBY also tran its the epithel i um and infects naive B-cel l s  in the underlying 
ti su . where i t  expre se a et of latent gen that cause the cel l s  to become activated 
and pro l i ferate a though it was responding to ant igen. This EBY transcript ion 
program the gro\\1h program, invol es 9 latent proteins, including nuclear ant igens 
E B  and membrane proteins LMPs. These proteins have a l l  the necessary 
activ i t ie to push the B-ce l ls  to become act i  ated b last without any necessity for 
external igna l ing. This cel l migrates to the fol l ic le ,  where the viral transcription 
progran1 changes. such that only 3 of the latent proteins are expressed : EB A I ,  
( required to repl icate the i ral D A) and 2 membrane proteins, LMP- l and LM P-2 
( the default program). ( 1 8)( ee figure 6 )  
Normal B-ce l l  EBV infection 
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The function of L P- I and LM P-2 have evo lved to teer the latentl infected 
B-ce l l  through the genninal cent r em i ronments. LM P-2 alone wi l l  push B- cel l to 
1'01111 a gellu inal cent r in the mu osal fol l ic le ,  LMP- l and LM P-2 can drive 
immunoglobin gene mutat ion and isotype switching, respectively, LMP- l 
dov.nregu late expre sion or the germ inal center regulatory transcription factor bcl -6, 
the ignal for a memory ce l l  to exit the gellu inal center. This impl ies coordinated 
expre ion of L 1 P- l  and LM P-2, where LM P-2 is turned on before and LMP- l i s  
turned on during the genninal center reaction. Thus constitutive expression of LMP- I 
in the ab ence of LM P-2 blocks genuinal center fonnation because the cel ls can never 
turn on bc l -6, an e ent ial  step in genninal center fonnation. ( 1 5) 
1.6.3. Maintenance 
Once in  the periphery, the latent ly infected cel ls shut down al l  v i ral protein 
expression ( the l atency program) and appear to be maintained as normal memory B­
cel l .  (16)  In  the early stages of 1M ,  the num ber of such cel l s  in the blood can reach 
staggering proportion, with 50% or more of a l l  memory cel l s  being infected. After 
that the resting memory B-ce l l s  in the periphery need to receive the T helper ( Th )  and 
B-ce l l s  Receptor ( BC R )  signals necessary to maintain their survival as memory cel ls. 
To do this, i t  is  bel i eved that they transit back through the nasophmyngeal 
lymphoepithel ium where they become act ivated and express the default program 
.Again LMP- l and LMP-2 gi e the necessary surv ival signals. The last component of 
persistent infection i s  the continuous shedding of infectious virus in the sal iva. 
Memory B-cel ls, transit ing the nasopharyngeal lymphoid ti ssue, wi l l  in i t iate virus 
repl ication and release the v irus back in the crypts. B-Ce l l s  that contain the virus 
repl icating vi rus in the lymphoepithe l i um have p lasma cel l  morphology. This would 
suggest that in  some c i rcumstances, the activated, latent ly i nfected, memory B-ce l l s  
d ifferent iate to p lasma cel l s  and release the v irus. (8) 
The growth program a l lows EBV to gain access to the memory compartment. 
Once the persistent infection is establ i shed, cel l  expressing the growth program m'e no 
longer essentiaL but continue to pose a threat to the host as the immune response 
attempts to c lear most vi ruses, it tends to select for strains with al tered epitope 
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equence that can no longer be recognized. The oppo ite is true for E BV .  It ha 
con en d the equence of grow th program latent protein that are recognized by 
c.)10toxic T lymphocyt s. The viru ha done thi to ensure that aberrant cel l 
expre ing the gro\\t1h program are rapidly k i l led and do not threaten the health of the 
ho t .  ( 48) 
1 .6 .... . Relea e 
B) acce mg the memory compartment, EBV has a site for long term 
per I tence. HO\\"ever. it must repl icate and be shed to spread to new hosts. S ignals 
that cause the B-ce l l s  to d ifferentiate into antibody secreting plasma cel l s  wi l l  in tum 
react ivate the viru . Because ant i body secreting plasma cel ls migrate to the mucosal 
epithel ium. uch a cel l  wi l l  be perfect ly  placed to re lease virus onto the mucosal 
urface. which in the case of the tons i l s  is a l iva. Thus infectious virus is  spread 
through sal i va contact. ( 1 5) 
1.7. E pstein-Ba rr virus a n d  m a lign a n cies 
Epstein  Barr v i rus is a common and potential l y  dangerous pathogen with 
capaci ty to contribute to the development of several mal ignancies. Most individuals 
expenence primary infection during early chi ldhood without c l inical ly important 
symptoms. 
However. if primary infection is del ayed unt i l  adolescence or beyond, i t  may 
be associ ated with the c l in ica l  syndrome of acute 1 M  (a lso known as glandular 
pharyngit is, V\ith fever. lymphadenopathy, hepati t is  and profound malaise .  The i l l ness 
may l ast for several weeks a l though it is a lmost a lways sel f- l imit ing. (48) 
The reason to bel ieve EBV might cau e cancer is  apparent E BV encodes genes 
that make B- cel l s  grow. Such genes wi l l ,  of their nature, have the potential as 
oncogenic risk factors. However, as described above, EBV has evolved to minimize 
the risk that an infected ce l l  wi l l  pro l i ferate out of contro l .  Therefore omething must 
go wrong with the nonnal vira l  b iology for EBV to play a causative role in tumor 
development. The plausib i l i ty of E B V  as an oncogenic virus has led to c laims of its 
association with many human tumors, some, such as breast and hepatocel lu lar 
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carcm rna, \\ h i  h hm'e never been sub tantiated . But there are no� several for which 
trong e\ idence e. i t .(. P )  inc luding immunoblastic lymphoma in immunosuppressed 
pat ient . Burk itt ' I) mphoma ( BL )  . Hodgkin's di ea e ( H D ), and na opharyngeal 
carcinoma ( P ). The origin f a l l  of the e tumor can be understood a arising from 
p i fic tage in the EBY l i fe c c le  and appear to be associated with the disturbance 
or the immune sy tem . ( 5 1 ) 
Per i tent infect ion i a ociated with se eral mal ignancies inc luding endemic 
Burkitt' I) mphoma. na ophyaryngeal carc inoma and Hodgkin lymphoma the pattem 
of ( Default program ) of EBY gene expression is characteri st ic .  
E B  infection in  the immunocompromised may result in uncontrol led virus 
dri\'en act i \  ation and prol i ferat ion of B-ce l l  with the development of 
lymphopro l i feration to momoclonal B-ce l l  lymphomas. In  this context the B-ce l l s  
expre s the fu l l  range of EBV l atent proteins (Growth program).  The tumors are 
increa ing problem. affecting both the tran p lant population and those with H IV 
infection. (48) 
1 . 7. 1 .  H odgki n ' s  Lym p ho m a  ( H D) 
Acute EBV infection in the adolescent -adult  can give rise to 1 M, long known 
to be a risk factor for H D. Howe er. the strongest evidence d irectly l i nk ing E BY with 
H D  came with the finding that approximately  40% of tumors contain c lonal E BY, 
which can approach 80% in  developing countries and up to 1 00% in  AID -re lated 
H D. I n  addit ion,  the tumor cel l s  express the default transcription program, which 
inc ludes 2 proteins ( LMP- l and LM P-2) that del i ver survival and gro�th signals ,  at 
least one of which ( L M P- l )  i s  known to act as an oncogene. ( 52) 
1.7.2. Bu rkitt' s  Ly m p homa ( B L )  
I t  is  named after Denis Parsons Burki t!" a surgeon who first described the 
disease in 1 956 whi l e  working in equatorial Africa ( see figure 7 ). It i a type of non­
Hodgki n's lymphoma (NH L )  that is sometimes cal led a B-cel l  lymphoma or smal l  
nonc leaved cel l lymphoma. Currently Burkitt's lymphoma can be divided into t hree 
main c l in ical variants : the endemic, the sporadic and the immunodefic iency-
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a c iated v ariant 'W hich are a l l  a ociated \\ ith H I V  and I D . Burkitts Lymphoma 
u ual l; a 0 iated with 0\ er 90% of A I D  cases. II facial features e hibited by 
Burkitt lymphoma arc a ociated \ ith H IV/ I D  . ( 53)  
Fig u re 7 :  even-) ea r-old N igerian boy w ith evera l months history of jaw sw el l i ng. The t u mor 
\\ as  u lcera ted a n d  d ra i n ing. (53) 
E B  was di covered in cultured tumor cel l s  from pat ients with the endemic 
form of Burkitt' lymphoma ( BL )  ( 5 2 ) .  The most compel l ing evidence of EBY's 
involvement in  BL is the high frequency (98%) of tumors carrying the E BV in 
endemic areas and the presence of c lonal EBV in a l l  of the tumor cel ls .  However, 
none of the growth promoting latent genes are expressed. The only genes expressed 
encoded for E B  A- I and the untranslated RNAs cal led E BE RS and BARTS. It has 
been suggested that E B  A- I and the EBERS might have oncogenic potentia l ,  but the 
fmding remain unsubstantiated and are controversial . Consequent ly, there i s  
currently no  broadly accepted understanding of the role of EBV in BL .  
( 1 5. 52) 
1 .7.3. N asopharyngeal  carc inoma ( N PC )  
Given the B-cel l  lymphotropism of E BV, i t  i s  surpri s ing that one of the best 
candidates for a tumor caused by E BV is not a lymphoma but a carc inoma, NPC, 
responsible for 20% of a l l  cancers in China and Taiwan and therefore an important 
world health problem. Virtual ly 100% of undi fferentiated N PCs worldwide contain 
c lonal EBV.  The tumors express the v iral default transcription program. Although 
only a subset, approximately 40%, express L M P- l ,  it has been reported that the 
premal i gnant lesion of PC al l  express LMP- l .  As with H D, the presence of LMP- ] 
and L M P-2 i s  additional evidence that the virus is playing a part in the cause of the 
tumor. Because LMP- l and LM P-2 are potently and speci fical ly evolved B-cel l 
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signal ing m lecule . their pr enc in the epithel ial cel l  of PC uggests the virus 
might be there fortuitou Iy . (5 \ )  
The potent ial role of EBY in N P  is c louded b our lack of certain knowledge 
ab ut the role of epithel ial  cel l in EBY lat ntly infects epithel ial  cel l s  that then 
proceed to repl i cate the virus and shed it in the sal iva. NPC would derive from such a 
latently infected, und ifferentiated epithel ia l  cel l .  which was blocked from switching to 
viral repl ication and therefore continues to be latently infected. ( \ 5 ) 
1 .8. E pstein Ba rr virus vaccination 
The fact that EBY is calTied by human as a l i felong latent infection and its 
abi l it) to immorta l ize and transfoml cel l s. Leads the scientist to d irect their researches 
to develop a \'accine, especia l ly when they found the apparent association between 
EBY and endemic BL and undifferentiated NPC .  
There are many reason affect the development of the E BV vaccine where the 
ab ence of c lear immunological basis . because of l imi ted understanding of the 
biology and immunology of the v irus and less knowledge about immunological 
criteria that are important in  preventing E BV -associated di sease has resulted in  slo\ 
progress . Furthermore. the cost of developing an EBV vaccine together with the lack 
of a strong commercia l  incentive to produce a vaccin against BL and N PC has also 
. ( '4 -5 '\6) delay vaccme development. . . . -
Three separate ways for contro l l i ng E BY -associated di sease by vaccine are 
under consideration. The first i s  to vaccinate with the major gp3 50 envelop 
glycoprotein and lor other envelop glycoprotein to modify EBY infection. A second 
approach would be to vaccinate at orne t ime after infection has taken place. It i s  
imagined that th i s  post infection approach could involve either envelop glycoprotein 
or latent antigen peptides or a combination of both .  The third tactic is  to use 
acc ination in a therapeutic mode to induce or enhance immune responses against the 
E BY -associated tumor cel ls .  Primary EBY infection in infants is usual ly 
asymptomatic, whereas, 1M occurs in  a proportion of individuals whose primary EBV 
infection has been delayed unti l adolescence. ( 8 ) 
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I herefore an B vaccine to prevent 1M \\- i l l  be more effective i f  targeted at 
population of eronegat iv e adole  cent in vve tern countrie , because a smal l  change 
1 11 1 111lTIUne tatu cau ed by \ accinat ion v\. i l l  b u ffic ient to prevent the disease. ny 
E B  v accine that could simply reduce the v iral load on primary infection, or direct an 
appropriate T-cel l  immune re pon e, rna be suffic ient to pre ent the manifestations 
f 1M therefore it i , rea nable to conclude that accination with gp350 to modify 
primary E B  infection could prevent 1 M . ( 56. 57. 8 ) 
I t  i s  d ifficult to imagine how vacc ine-induced re ponses could prevent the 
development of tumor such as NPC when the wide range of natural ly occurring 
immune re ponses could not . Po t infection immunization with gp350 or other type of 
\ acc ine. before the increase in EBY repl icat ion wil l  alter the immune balance at 
crucial t ime and prevent PC from de eloping. 
Th re are two strategies that ha e been fol lowed in the development of E BY 
vaccine that m ight be used to modify primary EBY infection. The first i s  based on 
the major envelop gl)  coprotein, gp3 50.  A second strategy is based on the 
identification of latent antigen peptide epitopes recognized by cytotoxic T­
lymphocyte ( CTLs) .  ( 8) 
1 .8. 1 .  G p350 Vacc ine  
The major EBY envelope glycoprotein gp350 was original ly selected as a 
candidate subunit vaccine to prevent EBY infection on the basis that antibodies raised 
against this molecule are v i rus neutra l i zing in vi tro . EBY gp3 50 contains up to 50% 
carbohydrate which may make the immunological profile  of gp3 50. Although at least 
20 open-reading frames in the EBY genome can potent ia l ly code for glycoproteins, 
only a fev. of these have been identi fied and characterized and their possible role in  
making an effective EBY vaccine has not received serious consideration to  date. ( 56) 
It has been establ i shed recent ly is  that gp350 is not an absolute requirement 
for E BY infection to occur. A recombinant EBY in which the gp3 50 gene had been 
deleted was found to be able to infect a range of B-cel l  l i nes and epithel ia l  cel l s, at a 
lower effic iency. Based on these results alone i t  would seem most un l ike ly that a 
gp3 50 vaccine would be able to prevent infection. However, these results do not rule 
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out an EB  gp3 0 vaccine being effective. (57. 8 )  Infe tion of epithel ial cel l in vitro 
ma) tak pia e by both gp 50 -dependent and independent pathways. 
The gp350-independent path ay include, Fir t EBY compon nt gp25,  where 
It wa found that E B  infection of an epithel ial cel l  l ine was not inh ibited by the 
pre ence of o luble gp350 but \ as inhibi ted b soluble gp25 ( the EBY homologue of 
herpe implex gL) .  The Second EBY membrane component is gp42, (, hich bids to 
M I IC  c la  s I I  molecules on the surface of B-cel ls ) .  EBY g350 binds to the host cel l  
complement receptor C D2 1  cross l ink ing o f  D2 1 by gp350 induces the synthesis of 
int rl ukin ( I L)- l to 6 and tumor necrosis factor. ( 8 )  
I ndeed it m ight be expected that gp350 could affect any cel l expressing C D2 1 .  
om work (8) has been performed in identifying gp350 B and T-cel l  epitopes with the 
,'iew of producing a gp3 50 pept ide vaccine. However at least two T- helper cel l  
epitope in the gp3 50 amino acid equence have been identified in  the amino terminal 
region. (5 5 )  
More recently_ gp350-spec ific CTL epitopes have been identi fied. I t  has now 
become apparent that CTL responses in the blood of 1 M  patient are mainly against 
lytic cycle ant igens, whi le  CTL responses in healthy seroposit ive persons can be 
d irected at ly1ic cyc le antigens as wel l  as latent antigens. ( 56 )  
Mal ignant lymphoma can be induced in the ew World primate ( the cottontop 
tramarin )  by injection of large doses of EBY and the tumors induced have been 
studied i n  some detai l .  The lymphoid lesions generated by the virus in this animal are 
c learly genuine tumors because they are monoclonal or o l igoc lonal, and arise 
i ndependent ly  at d ifferent sites in the injected animal . ( 5 5 . 8 )  
Types of EBY vaccines based on the envelope glycoproteins gp3 50 have been 
evaluated in the cottontop tamarin which inc lude. (57 )  
1 - The first subunit vaccine was based on gp3 50 purified from bu lk  cultures of  
EBY infected cel ls .  Th is  vaccine formulat ion induced virus-neutra l izing 
ant ibodies anda protect ive immune response in the cotton top tamarin model 
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or  EB lymphoma.(5
� ) n adjuvant could be incorporated with gp350 and 
introduc d a \ accine. which t imu late the immune re ponse to the subunit 
antigen ( gp350) .  Mo t of the adj utants used ar1 ificial  l i posome and immune-
t imulation complex ( I  om ) .  But the onl adj u ant cunentl l icensed for 
general human use are a lumin ium alL n alum adjuvant was tested in the 
tamarin lymphoma model with a recombinant gp350 subunit and was found to 
induce protective immun ity in three if fi e animals. ( 5 7) 
- A pia mid \ ector containing the gene for gp350 has been shown to induce 
effective immune respons s again t the antigen. The gp3 50 D A-vaccine 
induced gp3 50-speci fic antibodies. mainly of the IOg l i sotope, and could 
mediate anti bodies -dependent cel lular cytotoxic ity CADCC ) against cel l s  
expre s ing gp350 .The ector that has been used to introduce recombinant 
EBV gp 350  gene are denovi rus can be given oral ly which make it important 
factors in the future for induction of mucosal immuni ty in the form of I gA 
ant ibodies. ( 56) 
1 .8.2. Peptide vaccines 
EBV infection of B-<:el l  mainly gives rise to latent infection and only switches 
to productive infection under certain circumstances. E leven EBV genes, inc luding 
E B  A s  1 to 6 and L M Ps 1 .  2 A  and 2 B  are expressed i n  latent infection. I t  i s  bel ieved 
that the numbers of E BV infected cel l s  expressing the whole panel of E BNA and 
L M P  latent genes in the c irculation of human seroposit ive persons is very low and 
that this low level is l argely maintained by CTLs specific  for EBNA 3 .(8) 
E BV vaccination has been based in  these factors, and epitopes recognized by 
CD8+ CTLs against part icu lar M H C  backgrounds have been documented. Peptide 
vaccines based on these epitopes could be used to vaccinate a significant proportion 
of a given population provided the distribution if part icular MHC restrictions is  
known. The stated aim of this strategy i s  not to prevent infection but to reduce the 
number of v i rus-infected cel l s  that develop on infection and thereby reduce the 
incidence of di sease .human tria ls of an E BNA3 peptide that is  restricted through the 
human leukocyte antigen ( H L  ) B8 al lele are in progress. ( 5 7 )  
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1 . 9 .  OBJECTIVES: 
1 .  To detelmine the fr quency of EBV infection among United Arab 
Emirates at ionals .  
2 .  To detelmine th cau e of tonsi l lar and adenoid enlargement among 
nited rab Emirate ationals. 
3 .  To determine the type o f  infected cel ls .  
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I I . MATERI ALS & METH ODS 
II. MATERIALS & METHODS 
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I n  2009, AE  population stands at about 4 . 8  mi l l ion of  which approximately 
2 1 .  9% were nationals and the rest foreigners. (59) As a consequence, UAE nationals 
form a minority of those who reside in  the country. UAE has one of the most diverse 
populations in the M iddle East. 23% of the populations are -non cit izen Arabs or 
Persians and the majority of the population, about 50%, is from South Asia. The UAE 
high standard of l iving and economic opportunities have attracted workers from 
different part of the world such as, India, Pru l ippines, Egypt, Jordan, Yemen, 
Pakistan. ri Lanka and Bangladesh. " In  2007, there were approximately 1 .4 mi l l ion 
I ndian nationals residing in the UAE, making them the single l argest expatriate 
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ommunity " . ( 5Q) Th re i al 0 a izable population of people from Egypt, om al ia and 
udan \-\- ho migrated to the AE before it format ion. The U E ha al 0 attracted a 
mal l number of expatriate from developed countrie in Europe, orth America, 
A ia and Oceania. 
The population of the AE has a skewed se distribution consist ing of more 
than t\\ ice a man) maJe a female . The 1 5-65 age groups have a male/female sex 
rat io of 2 .743 .  The UAE gender imbalance is only surpassed by other Arab countries 
in the Per ian Gu lf  region. ( 60) 
The mo t populated c i ty i Dubai ,  i th approximately 1 .6 m i l l ion people. 
Other major c ities inc lude Abu Dhabi ,  A I -Ain,  Sharjah, and Fujairah. About 88% of 
the population of the Uni ted Arab Emirates i s  urban. The remaining inhabitants l i ve in 
t iny to\\TIS cattered throughout the country or in  one of the many desert oi l field 
camp in  the nation. The average l i fe e pectancy i s  78.24 years, h igher than any other 
(�9)  rab country . -
A l  in i s  the Eastern region of Abu-Dhabi bordering Oman . Al  Ain c i ty i s  
about 1 65 km from Abu Dhabi and 1 40 km from Dubai .  AI-Ain region covers an  area 
about of over 1 . 1 7  m i l l ion hectares. It most ly  has sand dunes and the temperature 
during the year ranges between 1 0DC up to 48DC. Al Ain city is considered as the 
country's centre of Ieaming, housing the UAE Universi ty and famous for its tourist 
dest inations. ( See figure 8) . (60) 
1 1.2. Resea rc h Eth ics 
The project has been approved by At  Ain di strict H uman research Ethical committee 
( protocol 0. 07- 1 45)  
I I. 3. M ate ria ls  
1 1 .3 . 1 .  Review of case 
Archival paraffin blocks of all the cases of tonsi l l ectomy and adenoidectomy 
for the period June 2004 through May 2005 were obtained from surgical pathology 
fi les of Tawam hospital in Al-A in c ity. I n  tota l ,  46 cases of tonsi l lectomy with 
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aden id tom; were random l) selected in bl indl \ ay from a total of 300 cases of 
ton i l le tom) and adenoidectomy pec imen. 46 paraffin blocks of tons i l lectomy 
pecimen and another 46 paraffin block of adenoidectomy specimens were a ai lable 
B r thi tud) . 
The a\ ai lable H matoxyl in  and eosm ( H&E)  and imm unohistochemical 
tained ction \vere reviewed. The age, sex, and c l in ical presentation were obtained 
b) rev iewing a l l  the histopathologic reports and request form of a l l  ca es. 
For the detection of E BV, two method were used to increase the speci fic ity 
and en i t iv i ty of this project, the immunohistochemical immunoperoxidase method 
to detect Ep tein Barr v im latent membrane antigen type I ( E BV -LMP- l ) and in situ 
hy bridization ( ISH) for EBV encoded RNA ( E BER) .  
I I . 4.  Methods 
1 1.4. 1. I m m u noh istochem istry ( m e) 
Immunohistochemical staining were performed using the fol lowing antibodies 
CD3 .  C D20, and E BV-LMP I .  A l l  sections were cut at 5 microns thickness and 
mounted on ami nopropyltriethoxys i lane (APES)  coated s l ides. After dewaxing with 
xylene and rehydrating \ i th alcohoL sl ides wi l l  be placed in a 0 .0 1 M c itrate buffer 
sol ution (pH=6.0) and pretreatment procedures to unmask the antigens wi l l  be 
performed in a microwave oven for 1 0  minutes. The sections were treated with 
peroxidase block for 20 m inutes fol lowed by protein block for 1 0  minutes. Then the 
primary antibodies were appl ied on sections with a concentration of 1 :50 for one hour 
at room temperature, after that we wash the sections in  phosphate buffer sal i ne ( PBS)  
for 1 5  m inutes in  three changes then we add the l ink antibody for 30  minutes a t  room 
temperature which were fol lowed by washing in PBS for 1 5  minutes. We add the 
label for 30  minutes at room temperature which were fol lowed by washi ng in PBS for 
1 5  minutes. The chromogen 3 '3-Diaminobenzidine chromogen ( DAB)  was then added 
for 1 0  minutes which is fol lowed by washing in PBS and counter staining with 
haematoxyl in .  F inaly the sections were dehydrated c leared and mounted in DPX. 
Lymph node ections were used as posit ive controls  for C D20, CD3 .  A Hodgkin 
Lymphoma posit ive case used as a posit ive control sections for EBY were used for 
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LMP- l . For n gati\ e control , pnmary antibod wa replaced with normal mou e 
erum. 
1 1.4.2. I n  s itu hybr id ization ( I S H )  
I n  itu hybridization was perfom1ed by using a speci fic o l igonucleotide probe 
\\ hich h. bridize to Epstein-BaIT v iru encoded RNA ( EBER)  transcripts 
conc ntrated in the nuclei of latently infected cel ls .  
Fi\  mIcron sections were mounted on APES coated sl ides, dewaxed and 
rehydrated . This was fol lowed b 30 minutes digestion with Proteinase K at 3 7°C . 
Twenty microl i ters of probe hybrid ization ol ution were added. The sl ides were 
incubated at 3 7°C for two hour then washed with TBS containing 0 . 1 % Triton x I OO.  
For detection, blocking solution (non11al rabbit serum di luted 1 : 5 in TBS, 
o ow/v B , 0. 1 % vi Triton x l  00) was added for 1 0  minutes, fol lowed by incubation 
with rabbit F ITC/AP (al kal ine phosphatase conj ugated ant ibody to fluorescein 
i sothiocyanate) for thirty minutes. 
After washing in TBS and alkal i ne phosphatase substrate buffer, the s l ides 
were i ncubated 0 emight with the solution containing 1 000 m icro l i ters of d i lute 
enzyme substrate and a lkal ine phosphatase buffer to which 1 micro l i ter of levamisole 
hydrochloride was added as an inhibitor. 
Fol lowing overnight incubation, sl ides were washed with water and 
counterstained with hematoxyl in .  With each batch of cases studied, a posit ive and a 
negati e contro l  s l ide were also run. The positive control s l ide was a known case of 
EBV posit ive t issue. to which was added the specific  EBER o l igonuc leotide probe. 
The negative control sl ide was another section of the same case of known E BV 
positive t issue to which was added a random probe consisting of a fluorescein labeled 
o l igonucleotide cocktai l .  I n  addition, for each case studied two sect ions were used ; the 
EBER o l igonucleotide probe was added to one section, and the random probe was 
added to the other. Using this random probe as a negative background control 
a longside the EBV probe contributes to the val idation of staining obtained by the 
EBV probe. I f  these negat ive control sl i des showed significant background staining in 
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a particu lar ca , the [ ide having th � B R probe wa considered Non-interpretable 
and the te t \'\'a repeated f r that particular ca e .  (6 1 )  
I I.4.3. Do u ble sta i n i ng tech n i q u e  
Fi\c-micrometer ection wer stained for E B E R  using in situ hybridization 
protocol \\ hich \'v a d cribed earlier. fter nuclear vi ualization primary anti bodies 
for C D20, CD3 and cytokerat in ere added for one hour at room temprature. The 
reaction was vi ualized by using alkal ine phosphatase kit  or streptavidin-biot in­
p roxida e method. 
1 1 .5 .  Sta t ist ical  Ana lysis 
The tat istical analysis was performed using SPSS for windows version 1 1  
( P  Inc. Chicago. USA)  and analyze - i t  ( Analyze- it software Ltd, Leeds, U K ) . 
tudenf t-test \\ as used to compare continuous variables. Quantitative variables 
were analyzed with the chi-squared test and correlations of ord inal variables using the 




IIL I .  Age Dist ri b u tion 
In  total ,  46 ca  e s  of ton i l l ectomy and adenoidectom were selected . I I  the 
ca were in the } 'I and econd decade of l i fe with predominant c lustering in the 1 51 
decade. The age d i  tribution i hown in ( Figure 9) .  
3 0  
2 5  
20 
1 5  
1 0  
5 
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0-9 1 0- 1 9  20-29 30-39 40-49 SO-59 60-69 
Figu re 9: Age a n d  gender d ist rib ution 
1 1 1.2. Gender  D istri b u tion 
• Female 
. Male 
Tola l  
In totaL 27 cases were females and 1 9  cases were males. The gender distribution is 
shov.TI in (F igure 9 ) . 
EBV expression correlation between age and gender 
era s tab and logistic regression show no signi ficant association between E BV 
expression and the age ( P  = 0 .324)  and gender ( P  = 0.442) distributions. ( See Table 1 )  
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Table I :  E BV expr ion correlation beh\ een age and gender 
EBV POSITIVE CASES EBV NEGATIVE CASES 
Age 
Female + Male + Total + Female - Male - Total -
0-9 6 8 1 4  6 8 1 4  
1 0-1 9 5 1 6 1 0  2 1 2  
20-29 0 0 0 0 0 0 
30-39 0 0 0 0 0 0 
40-49 0 0 0 0 0 0 
50-59 0 0 0 0 0 0 
Total  1 1  9 20 1 6  1 0  26 
1 1 1.3. E B V  D istri b u tion 
1 1 1 .3. 1 .  E BV p revalence i n  To ns i l lectomy spec i mens 
TOTAL CASES 
Female Male 
1 2  1 6  





27 1 9  
I n  total, 20 specimens were posit i  e by i n  situ hybridization method for EBER and 
sho'v\ the b lack  nuclear stain .  The frequency of EBV is shown in Table 2 and 
( Figure 1 0  and 1 1 ) . 
Only 5 ( 1 1 %) specImens of tonsi l lectomy show cytoplasmic and membranous 
positivity for LMP- l as shown in ( Figure 1 2 ) .  
3 3  
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Fig u re 1 0 : Tonsil la r ti sue show black n u clea r stain for E B E R  (a r row ), I n  s i tu hybrid izat ion,  
X400 
34 
Figu re 1 1 : Adenoid t issue how black n u clea r  sta i n  fo r E B E R  ( a r row), I n  sit u hyb rid iza t ion,  
X 400 
Figu re 1 2 : Ton s i l l a r  t is ue how membranous a n d  cytoplasm ic b row n stain for L M P- I  ( a r row ), 
I m m u no h i  tochemis t ry, X4000 
3 5  
1 1 1 .3.2. E BV prevalence in Adenoidectomy specimens 
In totaL 7 pecimen \ver po i t ive by in i tu hybridization method for EBER 
and hov" th  black nuclear tain. The frequ nc  of E BV is shown in Table 2 and 
( Figure J 2 ) . 11 tho e ea e \\- ere al 0 EBV po it i  e in their tonsi l lectomy spec imens. 
L 1 P- l  taining wa negative in al l 46 case adenoid specimens. 
1 1 1.4. Distr i bu tion of E B V  a mong lym phoid a nd epithel i a l  cel ls  
early 90% of the EBER-posit ive cel l s  were found within the B-ce l l -rich 
int rfo l l icu lar regions, ( Figure 1 3 , 1 4  and 1 5 ) whi le 1 0% were present within the B­
e l I -rieh genninal center of secondary fol l i c les (F igure 1 7 ) .  Nearly a l l  the EBER­
posit ive cel l s  were B cel l s . The E B ER-positive cel l s  show imm unoreactivity to C D20 
only ( Figure 1 5 . 1 6, 1 7  and 1 8 ) .  There was no immunoreactivity to C D3 (data not 
sho\\'J1) or cytokerat in ( data not shown) when using double staining method. 
I ndividual EBER positive cel l s  appeared to be randomly distributed within the 
interfo l l icu lar reg ions, whereas in germ inal centers the d istribution appeared to be 
random, with a few germ inal centers containing few posit ive cel ls .  
Stratified sq uamou 
� 
Figu re 1 3: Ton i l ler ti sue howing st ratified sq u a m ous epit heliu m ( t hic k a rrow ) in the exter n a l  
u rface a n d  lymphoid tissue con si t e d  of lymphoid fol l ic les ( t hin a rrow )  a n d  interfo l l ic u l a r  a rea 
( a r row head, H & E, X I OO. 
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Figu re 1 4 : Aden oid ti ue howing pseudostratified col u m n a r  ciliated epit heliu m ( t h ick a r row ) in 
t h e  e�ter n a l  su rface a n d  lym phoid tissue con sisted of lymphoid fol l ic les ( t hin a rrow ) a n d  
interfo l l ic u l a r  a rea (a r row h ead, H & E, X 1 00 )  
Figu re 1 5: Tonsil l a r  tissue wit h  d o u b l e  staining tec h n iq u e  showing double stained cells fo r 
E B E R  (a r row ), I n  sit u hyb ridiza tion, a n d  red m em b ranous staining for C D20 u ing a l ka line 
phosphata e detection kit, X400 
3 7  
Figu re 1 6: Ton i l l a r  t issue w i t h  dou ble sta i n i n g  tec h n i q u e  show i n g  dou ble s ta ined ce l ls for 
E B E R  ( a r ro\\ ),  I n  i t u  hybr id iza t ion,  a n d  red mem branous sta i n i n g  fo r CD20 us ing a l ka l i ne 
phosp bata  e detect ion kit,  X I 000. 
Figu re 1 7 : Ton i I I a r  ti ue w it h  dou ble t a i n i ng tec h n i q u e  show i n g  dou ble stai ned cells fo r E B E R  
(a r row ), I n  s i tu  hyb rid iza t ion,  a n d  b row n m e m b ra nous sta i n i n g  fo r C D20 us ing A BC- D A B  
detect ion k i t ,  X400. 
3 8  
Double  Sta i n  Positive for 
CD20 
Figu re 1 8 : Tonsi l l a r  t i  sue w i t h  dou ble sta i n i n g  tec h n i q u e  show i n g  dou ble stai ned c e l l s  fo r E B E R  
( a r row), I n  i t u  hy brid ization, a n d  b row n m e m b ra nous sta i n i n g  fo r C D20 us ing A BC-DA B 
detect ion kit ,  X l  000 
39  
IV. Disc u ss i o n  
I V. Disc ussion 
Enlargement of the ton i l  i a common finding in ch i ldren but the etiology 
b hind it remain controver in ! .  0 corr lation is found between Hype11rophic tons i l s  
and the b d) rna index in chi ldren. (62) The weight of nOlmal tonsi l s  in chi ldren i 
not w I I  docwnenled in anatomy l i terature� however, the mean weight of the 
ton i l lectom) 'pec imen from patho logic e, amination was shown to be 7.3 grams in 
chi ldr n b tv" een the ages o f 2  to 1 2  ears with 63% of it fal l s  between 5-8 grams. (63) 
Ton i l lectom) is a common urgical procedure in ch i ldren with the most common 
indication i tonsi l lar hypertrophy that leads to obstructive symptoms of the upper 
aH\\ n} . There is n poor con'elation between enlarged tonsi ls and the associated 
ymptom . (63 ) Recun'ent bacterial ton i 1 1 it is is considered to be the main reason for 
the enlargement of the tonsi ls: however, the bacteriological exam inations of the 
ton il howed that the re lationship is not very c lear. (64) Misuse of antibiotic therapy 
in a ute tonsi l l it i s  mal lead to change in tonsi l lar microflora and the imm unological 
pathophysiology predisposing to recurrent tonsi l l it i s  and subsequent colonization by 
various bacteria and viruses.(65) The role  of Actinomycosi s  i s  considered in the 
etio logy of recurrent tonsi l l it is ,  not as an active infection but as a factor in the 
development of lymphoid hyperplasia and hypertrophy.(66.67 ) Tons i l l i t i s  due to Human 
Herpe v i ru 6 ( HH V-6) infection has been shown to be associated with enlargement 
of the tonsi l s  even when the v iral  load is smal l .  (68) Colonization of the tons i l s  by EBV 
show no correlation between EBV -DNA quant ity and VCA-IgG quantity in the 
autologous sera. (69) EBV infection is very common, with a seroprevalence rates in 
excess of 90% worldwide (70) Nearly a l l  infections are acquired by oral contact with a 
person carrying EBV in sal iva. Although the exact deta i ls  of virus transmission in the 
oral cavity remain unknown, it is l i ke ly that init ia l  infection of either oral epithel ial 
cel l s  or tons i l l ar B-ce l l s  is fol lowed by a brief period of repl ication and l i felong 
persistence in B lymphocytes. (7 1 ) 
The cases are randomly selected from the surgical archi e of the pathology 
department at Tawam hospital for a period J une 2004-May 2005 . Tawam hospital is  
the main hospital that provides medical services for UAE nationals. Hence our 
amples which was randomly  selected is almo t representative ofthe UAE population. 
4 1  
I I  our ca e are chi ldren ince a im t a l l  the specimens of tonsi l lectomy and 
adenoidectomy belong to thi age group, which i imi lar to Endo et al study. ( 72) and 
indicate that ton i l lar and adenoidal hypertrophy occurs mainly during this age 
group. 
It i v.. e l l  known that EBV has a tropism [or the oral and nasopharyngeal 
region . and that i a ociated with lymphocyte pro l i ferat ion. The role of 
oropharyngeal epithel ial ce l l s as a reservoir of E BV was already suggested . (72) In the 
current tud) \\'e did not identi fied EBV within the epithe l ial cel l s  in tons i l  and 
adenoid pec imens indicat ing that B lymphocytes are the main reservoir for EBV in 
ton i ls  and adenoids. H unda l l  et  a J .  ( 73 ) showed that EBV is rarely found within 
epithel ial cel ls in  EBV - infected tonsi ls .  
Fol lowing primary infection in the oropharynx, E BV persists in  numerous 
anatomical i tes inc luding pharyngeal tonsi l , adenoids, lymph nodes, and peripheral 
b lood . I n  peripheral b lood, the v i rus is present in smal l rest ing memory B-cel ls  with 
latent gene e pression l imi ted to E BE R, LM P2a, and perhaps E BNA 1 .  (70) 
I t  i s  wel l  known that the interleukin 1 0  ( I L- I O) coding sequence IS highly 
homologous to the E B V  open reading frame BCRF l .  (74) 
BCRF 1 protein.  a lso termed i ral I L- I O  ( I L- I O ). i nh ib its the ynthesis of T -helper 1 
c}10kines ( 75 ). And cytotoxic T lymphocytes ( CTL) activity. ( 76) 
Therefore. E BV-associated antigen-specific CTL activity might be down­
regulated by v I L- I O  in EBV - infected areas of the tonsi l .  Hence, EBV is much more 
l i kely to surv i  e i n  the face of immune survei l l ance in the tonsi l s, suggesti ng that the 
immune response to EBV in tonsi l s  may be d ifferent from that in peripheral  blood. 
The prevalence of EBV infection in tons i l s  varies according to the detection 
method. tudies using the I H for detect ing EBER found a 26%, (
77 ) a 29%, (78) and a 
65% (79) association of the E BV with tons i l l i t is .  Whi le in  our study we found the 
prevalence of EBV infection in tonsi l s  to be 43%, which i s  intermediate between 
these studies and reflects a possible geographical d ifference in the prevalence of EBV.  
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The prevalence of E BY (43°'° ) in ton i l lectomy and adenoidectomy specimen 
E nat ional clo e to i t  prevalenc in Hodgk in lymphoma among AE 
nat ional ( 3 8°'0 ), ( 6 1 ) w hich may reflect a cau al re lationship between EBY and 
l Iodgkin I� mphoma. 
Id  nt i fication of a h igh ( 43%) prevalence of EBY-EBER in reculTing 
ton i 1 1 i t i  in chi ldren ugge t that the tons i l s  may be a reservoir for the EBY, and that 
thi v irus rna) be inv o lved in recUlTing infection. The prevalence of EBY in adenoids 
( 1  �%) is lower than tonsi ls (43%) in our study. This is  an interesting finding 
indicating a lower a sociation between adenoid hypertrophy and EBY infect ion. This 
tinding i d i fferent from that found by Endo et a ! .  (72) where he found the prevalence 
of EBY to be h igher in adenoids ( 5 7%) than tons i l s  ( 29%) and he used simi lar 
method for detection ( IS H ) . 
I n  thi study, the immunohi tochemical staining method is used for LMP- l 
with the aim of strengthening our results in  combination with EBER- ISH .  The fi nding 
was not encouraging as we have detected EBY in  only 5 cases ( 1 1 %) and in few cel l s  
w"i th in the  interfo l l icu lar area. This finding is less than that reported by E l iane et a l  
( 80) 
and this indicates a lesser expression of L M P- 1 in E BY infected cel ls .  In addit ion, it 
i ndicates that using EBER- ISH is the gold standard method for detecting EBY in 
t issue. Moreover. the use of EBER - ISH in the detection of EBY is more suitable s ince 
we can use i t  on paraffin-embedded tissue, which al lows us to test archive materia l  
when required. This  makes ISH superior to immunohistochemistry for LMP- 1 .  
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Table 3: Compari  on beh\-Cen o u r  t u dy a n d  other t u d ies 
Study Number of Method of Frequency of EBV 
peC lmen detection po i t ive pecimen 
Yoda et a l .  (77) 1 9  I S H  26% 
E o do et a l .  (/IS) 85 I S H  29% 
Cbaga et al. (7lJ) 38  I S H  65% 
P re eDt tudy 46 I S H  43% 
early al l  the EBV - infected cel l s  detected in  thi study of human tonsi ls  
appear to be smal l  C D20- posit ive B-cel l s  located primari ly in  the interfo l l icular 
reglOns. early 90% of the EBER-posit ive cel l s  were located within the T-cel l -rich 
interfo l l icu lar regions of the tonsi ls, whi le a significant number ( 1 0%) were located 
within the lymphocyte-rich fol l icu lar region. These results are consistent with 
previous tudies (8 1 .  82) 
I n  the present study, 1 0% of the E BER-positive cel i s, a l l  of which stained with 
C D20 B-ce l l s. were located within the B-ce l l -rich germinal centers of secondary 
fol l ic les. Few fol l ic les contained numerous EBER-posit ive cel ls .  These results are 
consistent with previous rep0l1s of EBER-posit ive germinal center B-ce l l s  in tonsi ls .  
(83 ) . I t  has been suggested that germ inal center centroblasts may be a site of E BV 
persistence. (84) The presence of EBV -posit ive B-ce l l s  in germinal centers is 
reportedly more common in tons i l s  from areas endemic  for E BV related lymphomas, 
leading to the suggestion that EBV -infected germ inal center B-ce l l s  may be more 
prone to mal ignant transformation, perhaps due to somatic hypermutation.
(83 ) 
In our stud we did not identify EBV within T-lymphocytes when we used 
C D3 monoclonal anti body to identify T-ce l l s. Hundal l  et a l . 
( 73 ) show that EBV is 
rarely found in T lymphocytes in EBV-infected tonsi ls .  
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There i orne contro\ er ) regarding the role of oropharyngeal epithel ia l  cel l 
l l1 B in fl cti n. It ha been ugge ted that primary and persistent EBV infection 
might be mediated thr ugh oropharyngeal epithel ial  cel l . ( 5 ) 
In  UppOlt for this notion ha come mainly from infection is detectable in 
de quamated orophary ngeal epithel ia l  cel l s  from patients with 1M by in situ 
cytohybridisat ion. ( 86) However, there is  now increasing evidence pointing to B-cel l s  
a the l ikely i te  of per i tent EBV infection, and also as  the possible target of primary 
EB infe tion. (87) Interestingly. se eral studies have demonstrated that E BV 
repl ication in oral hail)' leukoplakia is confined to the upper epithel ial  cel l  layers and 
i not accompanied by detectable latent infection of basal epithel ial  cel ls .(88. 89) Thus, 
these result do not support the idea that E BV persists in epithel ial  cel ls .  In our study 
we did not find E B V  in epithel ial cel l s  and E BV is detected only in B-ce l l s  and we 
think that B-ce l l  i s  the site of primary infection and latenc . 
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V. CONCLUSION & RECOMMENDATION 
v. CONCLU I O N  & R ECOM M E N DA T I O N  
Thi re earch ought to detelm ine the prevalence o f  E B V  i n  the tonsi ls  and 
adenoid of the United Arab Emirate (UAE)  Nationals and to provide a basis for 
under tanding the origin and biology of EBV-infected B and non-B cel ls .  E BV is 
a ociated \\ i th v arious type of tumors, inc luding nasopharyngeal carcinoma and 
Burkitt' I) mphoma. commonly cause infect ious mononuc leosis, Hodgk in lymphoma 
( H D) .  and ga tric carc inoma. 
a conelu  ion, the results of the research COnfil111 that EBV is prevalent in 
43°'0 of ton i ls and 1 5° ° of adenoid ; EBV is associated with tonsi l lar hypertrophy: a l l  
EB infected cel l s  are B lymphocytes and are predominant ly present in the 
interfo l l icu lar area; and in itu hybridization is the gold standard for detect ing EBV in 
t i  ue. 
fter l i t ing al l the research results the fol lowing recommendations can be 
given. Fir  t .  i t  i s  recommended using in situ hybridization for the precise detection of 
EBV in  t issue. Second, it i s  recommended to use in situ hybridization for EBER on 
uspected ca es. F inal ly, i t  is recommended to fol low-up on patients that are EBV­
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